Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.100728
Revised: October 8, 2024
Accepted: November 11, 2024
Published online: February 27, 2025
Processing time: 150 Days and 19.7 Hours
Gallbladder cancer (GBC) is known for its poor prognosis and challenging management. The preoperative fibrinogen to albumin ratio (FAR) has been proposed as a potential prognostic marker for predicting postoperative outcomes in GBC patients, but its efficacy and prognostic value remain underexplored.
To evaluate the prognostic value of preoperative FAR in GBC outcomes.
This retrospective cohort study included 66 patients who underwent curative surgery for GBC at our institution from January 2018 to January 2022. Preope
The cohort consisted of 36 male and 30 female patients, with a mean age of 61.81 ± 8.58 years. The optimal FAR cut-off value was determined to be 0.088, with an area under the receiver operating characteristic curve of 0.7899, sensitivity of 68.96%, and specificity of 80.01%. Patients with FAR ≤ 0.088 showed significantly better survival rates (1-year: 60.5%, 2-year: 52.6%, 3-year: 25.9%) and a median OS of 25.6 months (95% confidence interval: 18.8-30.5 months), compared to those with FAR > 0.088 who had a median OS of 10.8 months (95% confidence interval: 6.3-12.9 months).
Lower preoperative FAR is associated with longer OS in GBC patients, confirming its potential as a valuable prognostic indicator for improving outcome predictions and guiding patient management strategies in gallbladder cancer.
Core Tip: Our study explores the efficacy of the preoperative fibrinogen to albumin ratio (FAR) as a prognostic marker in gallbladder cancer (GBC), aiming to provide valuable insights into its potential utility in clinical settings. In this retro